BIOSPRING PARTNERS — 2022 Investments
1 investments dated 2022 · listed companies and verified rows first · show all
Abzenaabzena.comin𝕏Mar 2022 · $65M
Abzena is an integrated CDMO and CRO providing end-to-end development and cGMP manufacturing services for complex biologics and bioconjugates, including ADCs, AOCs, bispecifics, and HPAPIs.
Advanced ManufacturingBiotechHealthtechMedical DevicesCambridge, US
William John Edward Burt(Executive Officer, Director)Nigel Pitchford(Director)Leigh Pierce(Executive Officer)Kenneth Cunningham(Director)Julian Smith(Executive Officer, Director)Anthony Brampton(Director)
Co-investorsBeringeaWCASWelsh, Carson, Anderson & Stowe
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.